MK-1775: ATP-Competitive Wee1 Kinase Inhibitor for Cancer Research

Executive Summary: MK-1775 (Wee1 kinase inhibitor, A5755) is a potent, ATP-competitive inhibitor of the Wee1 kinase, displaying an IC₅₀ of 5.2 nM in cell-free kinase assays (APExBIO product page). It suppresses CDC2 phosphorylation at Tyr15, thereby abrogating the G2 DNA damage checkpoint (Schwartz 2022). MK-1775 demonstrates >100-fold selectivity for Wee1 over Myt1 kinase. It sensitizes p53-deficient tumor cells to DNA-damaging agents such as cisplatin, carboplatin, and gemcitabine. MK-1775 is insoluble in water and ethanol but is soluble in DMSO (>25 mg/mL); stock solutions are stable at -20°C for several months (APExBIO).

Biological Rationale

Wee1 kinase is a nuclear serine/threonine protein kinase that regulates cell cycle progression by phosphorylating cyclin-dependent kinase 1 (CDC2) at Tyr15. This phosphorylation event inhibits CDC2 activity and prevents premature entry into mitosis, maintaining the G2 DNA damage checkpoint (Schwartz 2022). In many cancers, loss of p53 function impairs the G1 checkpoint, forcing reliance on the G2 checkpoint for DNA damage repair and survival. Targeting Wee1 with small-molecule inhibitors like MK-1775 exploits this vulnerability, selectively sensitizing p53-deficient tumor cells to DNA-damaging chemotherapies (Related guide). This article extends previous overviews by providing granular, mechanistic data and workflow integration specifics for translational oncology workflows.

Mechanism of Action of MK-1775 (Wee1 kinase inhibitor)

MK-1775 is an ATP-competitive inhibitor that binds the catalytic site of Wee1 kinase, blocking its activity. This prevents the phosphorylation of CDC2 at Tyr15, abolishing the inhibitory signal that maintains G2 arrest in the presence of DNA damage. As a result, cells prematurely enter mitosis with unrepaired DNA, leading to mitotic catastrophe and apoptosis, especially in p53-deficient backgrounds (UMassChan Thesis). Key mechanistic points include:

• MK-1775 inhibits Wee1 with an IC₅₀ of 5.2 nM in cell-free kinase assays (APExBIO).
• It displays >100-fold selectivity for Wee1 over Myt1 kinase.
• By preventing CDC2 phosphorylation, it disrupts the G2 DNA damage checkpoint control.
• This effect is particularly pronounced in cells lacking functional p53, as these cells cannot activate the G1 checkpoint and therefore depend on G2 arrest (Schwartz 2022).

For a deeper dive into the translational implications and comparison to other ATP-competitive Wee1 inhibitors, see this analysis, which our article updates with new, testable benchmarks and protocol integration details.

Evidence & Benchmarks

• MK-1775 reduces CDC2 (CDK1) Tyr15 phosphorylation in a dose-dependent manner in p53-deficient cancer cell lines, with EC₅₀ values in the nanomolar range (Schwartz 2022).
• MK-1775 enhances cytotoxicity of DNA-damaging agents (gemcitabine, cisplatin, carboplatin) in vitro, with synergistic effects in p53-mutant models (Schwartz 2022).
• Wee1 inhibition by MK-1775 abrogates G2 checkpoint activation, resulting in increased mitotic entry and cell death following DNA damage (UMassChan Thesis).
• MK-1775 is soluble in DMSO (>25 mg/mL) and stable as a solid at -20°C for several months (APExBIO).
• MK-1775 shows moderate antiproliferative activity at higher concentrations in p53-mutant cancer cell models, independent of DNA-damaging agents (Schwartz 2022).

For a practical guide to integrating MK-1775 into cell viability assays and DNA damage response protocols, see this workflow article, which our current review clarifies with additional evidence and updated solubility parameters.

Applications, Limits & Misconceptions

MK-1775 (Wee1 kinase inhibitor) is widely used in research to:

• Study cell cycle regulation and checkpoint abrogation in cancer biology.
• Sensitize p53-deficient tumor cells to chemotherapy.
• Investigate DNA damage response pathways and synthetic lethality strategies.
• Screen for chemosensitizer effects in high-throughput assays.

However, certain misconceptions and limitations exist:

Common Pitfalls or Misconceptions

• MK-1775 does not restore p53 function; it sensitizes cells with defective p53 by targeting their reliance on the G2 checkpoint.
• MK-1775 is not broadly cytotoxic; its maximal effect occurs in combination with DNA-damaging agents and in p53-deficient models (Schwartz 2022).
• MK-1775 should not be stored as a solution at room temperature; long-term solution storage leads to degradation (APExBIO).
• MK-1775 does not inhibit all cell cycle kinases; it is highly selective for Wee1 and shows >100-fold selectivity over Myt1 kinase.
• Clinical efficacy in humans remains investigational; MK-1775 is intended for research use only.

This article clarifies misconceptions by providing direct, peer-reviewed evidence and explicit storage/handling recommendations, extending the coverage in prior mechanistic strategy guides.

Workflow Integration & Parameters

For optimal performance of MK-1775 (A5755, APExBIO) in cell-based research workflows:

• Preparation: Dissolve in DMSO at concentrations up to 25 mg/mL; avoid water or ethanol as solvents (APExBIO).
• Storage: Store solid at -20°C; DMSO stock solutions are stable for several months at -20°C, but repeated freeze-thaw cycles should be minimized.
• Dosing: Use nanomolar to low micromolar concentrations in vitro; titrate based on cell line sensitivity and assay endpoint.
• Controls: Include vehicle (DMSO) controls and, when evaluating chemosensitization, use at least one DNA-damaging agent (e.g., cisplatin at 1–10 μM, gemcitabine at 10–100 nM).
• Readouts: Assess CDC2 phosphorylation (immunoblot), cell cycle (flow cytometry), and cell viability/fractional killing (relative and fractional viability assays as described in Schwartz 2022).

For troubleshooting and advanced applications, refer to this application guide, which our article expands by specifying solvent compatibility and integrating fractional viability endpoints.

Conclusion & Outlook

MK-1775 (Wee1 kinase inhibitor, A5755) from APExBIO is a rigorously benchmarked tool for abrogating the G2 DNA damage checkpoint and sensitizing p53-deficient tumor models to DNA-damaging chemotherapies. Its high selectivity, robust in vitro performance, and detailed handling protocols make it a cornerstone for translational and basic cancer research. Continued optimization of workflow integration and mechanistic understanding will strengthen its role in DNA damage response studies and future combination therapy screens. For comprehensive product details, refer to the MK-1775 (Wee1 kinase inhibitor) product page.